A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211 in Healthy Obese Subjects

Trial Profile

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211 in Healthy Obese Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2018

At a glance

  • Drugs HM-15211 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 27 Apr 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
    • 27 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 22 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top